The following types of relationships may be deemed relevant include:

1. Stocks, stock options, or bond holdings in a for-profit corporation or self-directed pension plan
2. Research grants
3. Employment (full or part-time)
4. Ownership or partnership
5. Consulting fees or other remuneration (payment)
6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson
7. Receipt of royalties
8. Speakers bureau
9. Other (define below)

Abe, Asami, MD, PhD
2907 - Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings
Disclosure: Nothing to Disclose

Ablin, Jacob N
1837 - Validity of the Cognitive Index of the Symptom Severity Scale (SSS-Cog) in Assessing Cognitive Impairment in Fibromyalgia Patients
Disclosure: Nothing to Disclose

Aggarwal, Ishita, MD
2958 - Multi-Site Study Evaluating Performance on Lupus Nephritis Quality Measures
Disclosure: Nothing to Disclose

Ainsworth, Richard, PhD
920 - Rheumatoid Arthritis Patient-Specific Therapeutic Target Identification Using Integrative Epigenetic Profiling
Disclosure: Nothing to Disclose

Aizer, Juliet, MD, MPH
861 - Critical Appraisal Self-Efficacy and Learning Behavior in Rheumatology Trainees
Disclosure: Nothing to Disclose
Alehashemi, Sara, MD
894 - Cancer Risk in Ankylosing Spondylitis in United States Medicare Beneficiaries: Detection of a Chronic Non Steroidal Anti-Inflammatory Drug Use Signature
Disclosure: Nothing to Disclose

Alivernini, Stefano, MD, PhD
1933 - Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation
Disclosure: Nothing to Disclose

2830 - Synovitis in Psoriatic Arthritis and Seronegative Rheumatoid Arthritis: Differential Histological Features
Disclosure: Nothing to Disclose

Allen, Kelli, PhD
2945 - Culturally Enhanced Pain Coping Skills Training for African Americans with Osteoarthritis
Disclosure: Nothing to Disclose

Almeida de Jesus, Adriana, MD, PhD
926 - Truncating Mutations in SAMD9L Cause an Early-Onset Immune-Dysregulatory Syndrome of Neutrophilic Panniculitis, Interstitial Lung Disease and Cytopenias
Disclosure: Nothing to Disclose

Anandarajah, Allen P., MBBS, MD, MS
1843 - Improving Access to Rheumatology Care for High-Risk Lupus Patients Can Help Decrease Hospitalizations
Disclosure: Nothing to Disclose

Anderson, Erik, MD
1942 - Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus Associate with Decreased White Matter Integrity and Impaired Spatial Memory
Disclosure: Nothing to Disclose

Anquetil, Celine
2976 - Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis
Disclosure: Nothing to Disclose

Ardalan, Kaveh, MD, MS
1851 - Physical Function Trajectories in Children with Juvenile Myositis
Disclosure: Nothing to Disclose

Aringer, Martin, MD
2928 - Validation of New Systemic Lupus Erythematosus Classification Criteria
Disclosure: Nothing to Disclose

Arvikar, Sheila, MD
950 - Ultrasonographic Examinations Show Highly Prevalent Abnormalities of Hamstring Tendons in Lyme Arthritis Patients
Disclosure: Nothing to Disclose

Ashouri, Judith, MD
2900 - Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Disclosure: Nothing to Disclose

Aslam, Fawad, MBBS, MSc, RhMSUS
2874 - Comparison of Missing Data Reporting and Handling in Randomized Controlled Trials of Rheumatoid Arthritis Drug Therapy: A Snapshot Ten Years Apart
Disclosure: Nothing to Disclose

Assassi, Shervin, MD, MS
899 - Changes in the Systemic Sclerosis
Molecular Signatures after Myeloablation Followed By Autologous Hematopoietic Stem Cell Transplantation and Their Clinical Correlates
*Disclosure: Bayer, 2; Biogen Idec, 2; Boehringer Ingelheim, 2, 5; Momenta, 2*

Aterido, Adrià
921 - Multi-Omics Analysis Identifies a Gene Signature Associated with the Clinical Response to Anti-TNF Therapy in Rheumatoid Arthritis
*Disclosure: Nothing to Disclose*

Badley, Elizabeth M., PhD
1956 - Cohort Effects in Back Pain: The Effect of Changes in Life-Style and Co-Occurring Conditions
*Disclosure: Nothing to Disclose*

Baldini, Chiara, M.D, PhD
2884 - Correlation between Salivary Gland Ultrasonography, Minor Salivary Gland Histopathology and Sialometry: Towards a Composite Assessment of Salivary Gland Involvement in Primary Sjögren’s Syndrome
*Disclosure: Nothing to Disclose*

Ballal, Priyanka, MD
1920 - Is There Objective Evidence of Neuropathy in Knee Osteoarthritis Based on Clinical Evaluation?
*Disclosure: Nothing to Disclose*

Balzaretti, Giulia
2798 - Expanded T-Cell Clones Are Present in the Synovium before the Clinical Onset of Rheumatoid Arthritis
*Disclosure: Nothing to Disclose*

Baraliakos, Xenofon
897 - Prevalence of Inflammatory and Chronic Changes Suggestive of Axial Spondyloarthritis in Magnetic Resonance Images of the Axial Skeleton in Individuals < 45 Years in the General Population as Part of a Large Community Study (SHIP)
*Disclosure: Nothing to Disclose*

2925 - Fatty Lesions Detected on MRI Scans in Patients with Ankylosing Spondylitis Are Based on the Deposition of Fat in the Vertebral Bone Marrow
*Disclosure: Nothing to Disclose*

Barazani, Sharon, BS
2964 - Detection of Uric Acid Crystals in the Vasculature of Patients with Gout Using Dual-Energy Computed Tomography
*Disclosure: Nothing to Disclose*

Barbarroja, Nuria, Doctor
1848 - Cardiovascular Risk Factors in Adults with Juvenile Idiopathic Arthritis in Sustained Remission
*Disclosure: Nothing to Disclose*

Barber, Claire, MD, PhD
2960 - Evaluation of Performance Measures Reveals Delays and Sub-Optimal Access to Rheumatology Care and Treatment
*Disclosure: Nothing to Disclose*

Barbhaiya, Medha, MD, MPH
2806 - Childhood Physical and Sexual Abuse and Risk of Systemic Lupus Erythematosus Among African American Women
*Disclosure: RRF, 2*

2805 - Association of Dietary Quality Scores and Incident SLE in the Nurses’ Health Studies
*Disclosure: RRF, 2*
Barbulescu, Andrei  
960 - The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study  
Disclosure: Nothing to Disclose

Barracough, Michelle, PhD  
1941 - Altered Cognitive Function in Systemic Lupus Erythematosus and Associations with Inflammation and Functional Brain Changes  
Disclosure: Sanofi Genzyme, 2

Barron, Karyl, MD  
1911 - The Expanding Clinical Spectrum of Patients with Deficiency of Adenosine Deaminase 2 (DADA2)  
Disclosure: Nothing to Disclose

Barsotti, Simone, MD  
2979 - Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT  
Disclosure: Nothing to Disclose

Bartels, Christie M., MD, MS  
1845 - Defining and Examining Retention in Care in an Urban Lupus Cohort  
Disclosure: Pfizer, Inc., 2

Bartlett, Susan J., PhD  
2984 - Lifestyle and MTX Use Are the Strongest Predictors of Not Achieving Remission in the First Year of Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH)  
Disclosure: Lilly, 5; Novartis, 5; Pfizer, Inc., 5; UCB, Inc., 5

Barton, Jennifer, MD  
1892 - Patient and Health System Characteristics Associated with Receipt of Disease Modifying Anti-Rheumatic Drugs in a National VA Sample  
Disclosure: Nothing to Disclose

1925 - Goal Concordance in Rheumatoid Arthritis: Beyond Pain Reduction, Is There Agreement?  
Disclosure: Nothing to Disclose

Bergstra, Sytske Anne  
1840 - Disease Activity in Rheumatoid Arthritis Patients Is Influenced By Countries' Socioeconomics: Results from the Meteor Registry  
Disclosure: Nothing to Disclose

Berti, Alvise  
905 - Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis  
Disclosure: Nothing to Disclose

Best, Jennie H., PhD  
2995 - Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis  
Disclosure: Genentech, Inc., 3

Bettner, Leah F.  
1863 - Anti-Cyclic Citrullinated Protein Antibody at Multiple Cutoff Levels and in Combination with Rheumatoid Factor IgM and Serum Calprotectin Is Highly Specific for the Development of Rheumatoid Arthritis within 3 Years  
Disclosure: Nothing to Disclose

Bhardwaja, Bharati, PharmD  
2861 - Clinical Laboratory Telephone Communication Outreach to Rheumatology
Patients Improves Guideline-Concordant Timeliness of Monitoring of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Disclosure: Nothing to Disclose

Bhuyan, Farzana, PhD
2854 - Majeed Syndrome Causing LPIN2 mutations May Prevent Bone “Healing” By Rendering M2 Macrophage Proinflammatory
Disclosure: Nothing to Disclose

Blanco, Irene, MD, MS
1841 - Current Rheumatology Fellows Experiences with Health Disparities and Disparity Education: A Qualitative Study
Disclosure: Nothing to Disclose

Blazer, Ashira, MD, BS
1943 - Apolipoprotein L1 Risk Variants Associate with Poor Renal Outcomes, Damage Accrual, and Death: A Prospective Ghanaian SLE Cohort
Disclosure: Nothing to Disclose

Boers, Maarten, Prof. Dr.
2982 - Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up
Disclosure: Nothing to Disclose

Boeters, Debbie M., MD
2953 - Disappearance of Autoantibodies in RA: Does It Occur with Current Treatment Strategies? a Long-Term Follow-up Study in Patients That Achieved DMARD-Free Sustained Remission
Disclosure: Nothing to Disclose

Boire, Gilles, MD, MSc
2983 - The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study
Disclosure: Bristol-Myers Squibb, 2

BOLKO, Lois
878 - IFN Level Assessed By Ultrasensitive Detection Technology in Myositis Patient: A Promising Biomarker of Disease Activity in Dermatomyositis and Anti-Synthetase Syndrome
Disclosure: Nothing to Disclose

Bosello, Silvia Laura, MD, PhD
2936 - Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis
Disclosure: Nothing to Disclose

Boulos, Daniel, MBBS (Hons)
1929 - The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure
Disclosure: Nothing to Disclose

Brady, Teresa, PhD
2941 - Reach and Effectiveness of a Health Communications Campaign Promoting Self Management Education: Results of a Pilot Test of the Learn More. Feel Better. Campaign
Disclosure: Nothing to Disclose

Brahe, Cecilie Heegaard, MD
1867 - Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
Disclosure: Novartis Pharmaceuticals AG, 2

2821 - Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year
Outcomes and Predictors  
*Disclosure: Nothing to Disclose*

**Brittan, Kaitlyn, MD**  
943 - Risk of Prostate Cancer in US Veterans with Rheumatoid Arthritis  
*Disclosure: Nothing to Disclose*

**Brunner, Hermine I.**  
2867 - Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus  
*Disclosure: AbbVie, Amgen, Biogenidec, Alter, AstraZeneca, Baxalta Biosimilars, Biogenidec, Boehringer, BMS, Celgene, CrescendoBio, EMD Serono, F. Hoffman-La Roche, Janssen, MedImmune, Novartis, Pfizer, Sanofi Aventis, Takeda, and UCB Biosciences GmbH, 5; GlaxoSmithKline (GSK), F. Hoffman-La Roche, Novartis, Pfizer, Sanofi Aventis, Merck Serono, 5*

**Bubb, Michael R, MD**  
2869 - Incorporation of Patient Reported Outcomes Data in the Care of US Veterans with Rheumatoid Arthritis: A Randomized, Controlled Trial  
*Disclosure: Nothing to Disclose*

**Buckley, Chris, FRCP, PhD**  
1938 - A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate  
*Disclosure: GlaxoSmithKline, 5*

**Burmester, Gerd R.**  
L18 - A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab  
*Disclosure: Roche, Sanofi, Genzyme, 5, 8*

**Buyon, Jill P., MD**  
1855 - Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus  
*Disclosure: Exagen, 2*

**Byram, Kevin, MD**  
2838 - Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database  
*Disclosure: Nothing to Disclose*

**Cannon, Grant W., MD**  
2857 - An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry  
*Disclosure: Nothing to Disclose*

**Carron, Philippe, MD, PhD**  
2831 - High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis  
*Disclosure: Nothing to Disclose*

**Casey, KA**  
975 - Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study  
*Disclosure: AstraZeneca, 1; MedImmune, 3*

**Chakraborty, Debomita**  
1900 - FGFR3/FGF9 Regulates the Activity of Profibrotic Cytokine and Growth Factor
Pathways to Drive Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis  
*Disclosure: Nothing to Disclose*

**Chalmers, Samantha**  
2851 - NF-Kappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis  
*Disclosure: Nothing to Disclose*

**Chandrasekharan, Unnikrishnan M, PhD**  
841 - TNFR2 Inactivation Reduces Psoriatic Inflammation in Mice Via Down-Regulating Dendritic Cell Expansion and Inhibiting IL-23/IL-17 Pathways  
*Disclosure: Nothing to Disclose*

**Chang, Alison H.**  
955 - Lower Limb Muscle Strength and Protection Against Functional Decline and Structural Worsening in Knee Osteoarthritis  
*Disclosure: Nothing to Disclose*

2962 - Diagnostic Accuracy of Gout in Electronic Health Records and the Role of Rheumatology Electronic Consults  
*Disclosure: Nothing to Disclose*

**Charrier, Manon**  
934 - HIV Protease Inhibitors Cure Lupus-Prone Mice and Prevent T Helper 17 Cell-Driven Inflammation By Inhibiting CD95-Non-Apoptotic Signaling Pathway  
*Disclosure: Nothing to Disclose*

**Chen, He**  
875 - Anti-Calreticulin Antibody – a Novel Antibody in Patients with Idiopathic Inflammatory Myopathies and Its Association with Malignancy  
*Disclosure: Nothing to Disclose*

**Cheng, Anyan**  
2965 - Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation  
*Disclosure: Nothing to Disclose*

1934 - microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis  
*Disclosure: Nothing to Disclose*

2827 - Remission Targets and Prevention of Subclinical Atherosclerosis in Psoriatic Arthritis- Which Target Should We Choose?  
*Disclosure: Nothing to Disclose*

**Choudhary, Gourav, M. Tech.**  
939 - Rab4A Protects from Lupus Nephritis By Limiting Germinal Center Formation and Pro-Inflammatory Expression of GLUT1 and Integlin By Renal Epithelial Cells  
*Disclosure: Nothing to Disclose*

**Chung, Cecilia P., MD, MPH**  
1919 - Individual Short-Acting Opioids and the Risk of Opioid-Related Adverse Events in Adolescents  
*Disclosure: Nothing to Disclose*

1839 - Association of Diet Quality with Overall Fibromyalgia Impact, and Psychosocial and Quality of Life Outcomes in Women with Fibromyalgia  
*Disclosure: Nothing to Disclose*

**Coates, Laura C., MD**  
2886 - Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies  
*Disclosure: AbbVie, Amgen, BMS, Celgene, Pfizer, UCB, MSD, Boehringer Ingelheim, Novartis, Lilly, Janssen, Sun Pharma,
Cohen, Stanley, MD
963 - Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
Disclosure: Pfizer Inc, 2, 5

Collins, Jamie E., PhD
915 - The Association between Structural and Symptomatic Progression in Knee Osteoarthritis
Disclosure: Nothing to Disclose

Consolaro, Alessandro, MD, PhD
2916 - New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients
Disclosure: Nothing to Disclose

Corciulo, Carmen, PhD
848 - A2A Adenosine Receptor Stimulation Switches TGF-β Signaling to Promote Chondrocyte Proliferation and Cartilage Regeneration
Disclosure: Intellectual property, 9; Regenosine, 1

Costenbader, Karen, MD, MPH
2996 - The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Medicaid Cohort Stratified By Disease Severity
Disclosure: AstraZeneca, 5; GlaxoSmithKline, 5; Merck & Co., 5

Coury, Fabienne
1824 - Osteoclast Derived-Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss
Disclosure: Pfizer, Inc.; Abbvie; Novartis; MSD, 5

Criado, Gabriel, PhD
932 - Fibroblasts Senescence Is Observed in Rheumatoid and Osteoarthritic Synovial Tissues and Triggers a Pro-Inflammatory Program Ex Vivo
Disclosure: Nothing to Disclose

Crofford, Leslie, MD
L19 - Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
Disclosure: Nothing to Disclose

Curtis, Jeffrey R., MD, MS, MPH
885 - Herpes Zoster in Tofacitinib Users with and without Concomitant Methotrexate and Glucocorticoids
Disclosure: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Radius, Roche/Genentech, UCB, 2, 5
958 - Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting
Disclosure: AbbVie Inc., 2, 5; Amgen Inc., 2, 5; BMS, 2, 5; Corrona, LLC, 2, 5; Eli Lilly, 2, 5; Janssen, 2, 5; Myriad, 2, 5; Pfizer, Inc., 2, 5; Radius, 2, 5; Roche/Genentech, 2, 5; UCB, Inc., 2, 5
1940 - Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
Disclosure: Abbvie, Amgen, BMS, Corrona, Janssen, Lilly, Myriad, Pfizer, Roche/Genentech, UCB, 2, 5
2814 - Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
*Disclosure: AbbVie Inc., 2, 5; Amgen Inc., 2, 5; BMS, 2, 5; Corrona, LLC, 2, 5; Eli Lilly, 2, 5; Janssen, 2, 5; Myriad, 2, 5; Pfizer, Inc., 2, 5; Radius, 2, 5; Roche/Genentech, 2, 5; UCB, Inc., 2, 5*

**Cuthbert, Richard, PhD**
1833 - The Vδ2 Subset of Γδt-Cells Are Present at Healthy Human Enthesis and Have Transcriptional and Functional Characteristics Consistent with a Capacity for IL-17A Production in Response to IL-23
*Disclosure: Nothing to Disclose*

**Dalbeth, Nicola, MD**
2969 - Allopurinol Dose Escalation Slows Progression of CT Bone Erosion in People with Gout: Imaging Sub-Study of a Randomized Control Trial
*Disclosure: AbbVie Inc., 8; Amgen Inc., 2; AstraZeneca/Ironwood, 2; Horizon, 5; Janssen, 8; Kowa, 5; Pfizer, Inc., 8*

**Dall’Era, Maria, MD**
1870 - Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF (Belimumab) in Patients with Active Lupus Nephritis
*Disclosure: AstraZeneca, 5; Genentech, Inc., 5*

**Danila, Maria I., MD, MSc, MSPH**
1924 - Mitigating Medication Risk Aversion in the Confident Treatment Decisions for Living with Rheumatoid Arthritis Trial
*Disclosure: Pfizer, Inc., 2*

**Dau, Jonathan, M.D.**
895 - Associations of Statin Usage with Disease Activity in Ankylosing Spondylitis
*Disclosure: Nothing to Disclose*

**Davis, Julie, BS**
952 - Effusion-Synovitis and Infrapatellar Fat Pad Edema Differentiate Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative
*Disclosure: Nothing to Disclose*

**Davis-Porada, Julia**
1854 - SLE Flares during and after Pregnancy Are Mild and Occur at Similar Rates
*Disclosure: Nothing to Disclose*

**De Benedetti, Fabrizio, MD, PhD**
2864 - Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Systemic Juvenile Idiopathic Arthritis
*Disclosure: Abbvie, Sobi, Novimmune, Roche, Novartis, Sanofi, UCB, Pfizer, 2*

**De Cillis, Verónica, OTR**
1949 - Implementation of a Health Diary for Patients with Fibromyalgia
*Disclosure: Nothing to Disclose*
de Pablo, Paola
1905 - Lower Education Level Is Associated with Higher Risk of Developing Rheumatoid Arthritis
Disclosure: Nothing to Disclose

Decarriere, Guillaume
2822 - Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Disclosure: Nothing to Disclose

Dein, Eric, MD
2939 - Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis
Disclosure: Nothing to Disclose

Deodhar, Atul A., MD, MRCP, FACP, FACR
1868 - Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)
Disclosure: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma, 2, 5

Dervieux, Thierry, PharmD., PhD
1858 - An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis
Disclosure: exagen, 3

Deshmukh, Vishal, PhD
1952 - Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway
Disclosure: Samumed, LLC, 1, 3

Dhital, Rashmi, MD
2813 - Risk of Venous Thromboembolism with Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Trials
Disclosure: Nothing to Disclose

Distler, Oliver, Prof. Dr. med.
903 - Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)
Disclosure: Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemolmAb, espeRare foundation, Genentech/Roche, GSK, Inventiva, Italfarmaco, Lilly, medac, MedImmune, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sanofi, Sinoxa, UCB, 5; Actelion, Bayer, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Roche, 2; Patent mir-29 for the treatment of systemic sclerosis licensed, 9

Dooley, Mary A.
971 - A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis
Disclosure: Nothing to Disclose

Dörner, Thomas, MD
1894 - Baricitinib-Associated Changes in Type I Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
Disclosure: AbbVie, Celgene, Eli Lilly and Company, MSD, Novartis, Pfizer, Roche, UCB, 5; Amgen, Biogen, Celgene, 8; Chugai, Janssen, Roche, Sanofi, 2

Dorris, Emma, PhD
918 - A Novel Familial RELA Truncation Is
E. Najem, Catherine, MD, MSCE
906 - Defining the Gut Microbiome in Patients with ANCA-Associated Vasculitis
Disclosure: Nothing to Disclose

Edens, Cuoghi, MD
2961 - Differences in Healthcare Transition Views, Practices, and Barriers Among North American Pediatric Rheumatology Providers from 2010 to 2018
Disclosure: Nothing to Disclose

Eder, Lihi
966 - Central Triage Clinic for Psoriatic Arthritis – Performance of Triage Methods
Disclosure: UCB, Celgene, Novartis and Jensen, 2

967 - Health Care Utilization for Musculoskeletal Issues during the Pre-Diagnosis Period in Psoriatic Arthritis – a Population-Based Study
Disclosure: Nothing to Disclose

England, Bryant R., MD
880 - Serum Cytokine and Chemokine Concentrations Predict Incident Cancer in US Veterans with Rheumatoid Arthritis
Disclosure: Nothing to Disclose

Espinosa, Maria, MD
2828 - Utility of Fecal Calprotectin Levels for the Diagnosis of Inflammatory Bowel Disease in Patients with Spondyloarthritis
Disclosure: Nothing to Disclose

Falgarone, Geraldine
1826 - From Cancer to Autoimmunity: A New Model of Rheumatoid Arthritis Emerging from a Constitutional Genetic
Approach Used in Low Penetrance Cancers
Disclosure: Nothing to Disclose

Farris, A. Darise, PhD
2799 - Sjogren’s Syndrome Minor Salivary Gland CD4+ T Cells Associate with Oral Disease Features and Have a T Follicular Helper-like Transcriptional Profile
Disclosure: Nothing to Disclose

Fava, Andrea, MD
Disclosure: Nothing to Disclose

Feldman, Candace H., MD, MPH, ScD
2807 - Association of Exposure to Childhood Abuse with Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women
Disclosure: Nothing to Disclose

2959 - Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study
Disclosure: Nothing to Disclose

Fell, Andrew
977 - Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimilar in Patients with Juvenile Idiopathic Arthritis and Uveitis - a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies
Disclosure: AbbVie Inc., 8

Ferrada, Marcela A., MD
2973 - Clinical Features and Pulmonary Function Test Findings Associated with Large Airway Disease in Relapsing Polychondritis
Disclosure: Nothing to Disclose

Ferrari, Serge
2808 - T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Disclosure: Amgen, UCB, AgNovos, 5; UCB, MSD, Amgen, 2

2809 - Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed
Disclosure: Amgen, UCB, AgNovos, 5; UCB, MSD, Amgen, 2

Fleischmann, Roy
890 - A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Disclosure: AbbVie, Lilly, Pfizer, Gilead, 2, 5

Fonseka, Chamith, BS
2903 - Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis
Disclosure: Nothing to Disclose

Ford, Julia, MD
1910 - Impact of Cyclic Citrullinated Peptide Autoantibody Level on Progression to Rheumatoid Arthritis Among CCP-Positive Patients without RA in a Clinical Setting
Disclosure: Nothing to Disclose
Fortea-Gordo, Paula, PhD
2898 - Increased Frequency of Circulating CD4+CXCR5-PD1 hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)
Disclosure: Nothing to Disclose

Fraenkel, Liana, MD, MPH
2910 - Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials
Disclosure: Nothing to Disclose

Franks, Jennifer, BS
919 - A Machine Learning Classifier for Assigning Individual Patients with Systemic Sclerosis to Intrinsic Molecular Subsets
Disclosure: Nothing to Disclose

Fu, An-Chen, MS
872 - Is the Serum Uric Acid Therapeutic Target Protective of Chronic Kidney Disease, Cardiovascular Disease, and Mortality for Patients with Gout? a Longitudinal Study
Disclosure: Ironwood Pharmaceuticals, Inc., 1, 3

Gandolfo, Saviana, MD
2880 - Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation
Disclosure: Nothing to Disclose

Gaylis, Norman B
1936 - A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Disclosure: Nothing to Disclose

Gelber, Allan C., MD, MPH, PhD
860 - Efficacy of a Web-Based Module to Educate Internal Medicine Housestaff on Gout
Disclosure: Nothing to Disclose

Genovese, Mark C., MD
962 - Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
Disclosure: AbbVie, Eli Lilly and Company, Galapagos, Gilead, Pfizer, 5

Funck-Brentano, Thomas, MD PhD
956 - Bone Mineral Density Is a Causal Risk Factor for Knee and Hip Osteoarthritis: A Population-Based and Mendelian Randomization Study in the UK Biobank
Disclosure: Nothing to Disclose

Gao, Anqi
1822 - RNA-Sequencing of Mouse and Human Synovial Fibroblasts Reveals Fibroblast Subset-Specific Responses to Inflammation
Disclosure: Nothing to Disclose

Funck-Brentano, Thomas, MD PhD
1866 - Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Disclosure: AbbVie, Eli Lilly and Company, Galapagos, Gilead, Pfizer, 2, 5

Giles, Jon T., MD, MPH
1862 - Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Very Low Circulating Low-Density Lipoprotein Concentration Levels Are Associated with Pro-Atherogenic Biomarkers
Disclosure: Nothing to Disclose

Glerup, Mia
980 - Long-Term Outcome of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Results of 18-Year Follow-up in the Population-Based Nordic JIA Cohort
Disclosure: Nothing to Disclose

1849 - Remission Status after 18 Years of Follow-up in the Population-Based Nordic Juvenile Idiopathic Arthritis (JIA) Cohort
Disclosure: Nothing to Disclose

Golder, Vera, MBBS BMedSci FRACP
2930 - Prospective Comparison of Remission and Lupus Low Disease Activity State - Effect on Disease Outcomes in Systemic Lupus Erythematosus
Disclosure: Nothing to Disclose

Goldhar, Hart, MD
2988 - Characteristics and Outcomes in a Prospective Cohort of Patients with Aortitis Diagnosed Following Surgical Resection
Disclosure: Nothing to Disclose

Goldin, Jonathan, MD, PhD
901 - Changes in Quantitative Scleroderma Lung CT Measures in Patients Treated with Cyclophosphamide or Transplantation
Disclosure: Nothing to Disclose

Gomez, Alejandro
2791 - Characterization of Monoclonal Anti-PAD4 Autoantibodies from Rheumatoid Arthritis Patients: Functional Implications for Citrullination and Disease Progression
Disclosure: Nothing to Disclose

Gono, Takahisa
2980 - Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
Disclosure: Astellas Pharma, 8

Goode, Adam P., DPT, PhD
911 - Demographic and Clinical Characteristics Reflect Differences in Osteoarthritis Phenotypes of the Lumbar Spine: The Johnston County Osteoarthritis Project
Disclosure: Nothing to Disclose

Goodman, Susan M., MD
1932 - Complications Following Total Knee Arthroplasty in Inflammatory Versus Osteoarthritis
Disclosure: Roche, Novartis, 4

Gorelik, Mark, MD
922 - Anakinra Treatment Prevents Myocardial Mechanical Dysfunction and Inhibits Histologic Evidence of Myocardial Inflammation in the Mouse Model of Kawasaki Disease
Disclosure: Nothing to Disclose

Gossec, Laure
965 - Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436
Gota, Carmen E., MD  
1834 - Sleep Apnea and Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry  
Disclosure: Nothing to Disclose

Gravallese, Ellen M., MD  
1830 - Role of BMP2 in Enthesal Bone Formation in Inflammatory Arthritis  
Disclosure: AbbVie Inc., 2, 3, 7

Gribbons, Katherine B., BS  
1881 - Discovery and Validation of Novel Disease Subsets in 806 Patients with Takayasu’s Arteritis across Four International Cohorts  
Disclosure: Nothing to Disclose

Grund, Eric, PhD  
2932 - Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology  
Disclosure: BERG, LLC, 1, 3

Guglielmo, Dana, MPH  
1950 - Self-Reported Depression and Anxiety Among US Adults Aged 18-44 Years with Arthritis, National Health Interview Survey 2014-2016  
Disclosure: Nothing to Disclose

Gul, Hanna, Dr (MBCHB, MRCP)  
2824 - On Tapering Therapy for RA Patients in Clinical Remission; Flare on CsDMARDs Predicted By Clinical Features and Musculoskeletal Ultrasound, Whereas T-Cell Abnormalities Predictive for b-DMARD Tapering  
Disclosure: Nothing to Disclose

Hammaker, Deepa, PhD  
930 - Joint Location-Specific IL6 and JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)  
Disclosure: Nothing to Disclose

Hammer, Hilde B, MD PhD  
2868 - Tender Joint Count May Not Reflect Inflammatory Activity in Established Rheumatoid Arthritis Patients; Results from a Longitudinal Study of Tocilizumab  
Disclosure: AbbVie Inc., Novartis, 8

Hanly, John G., MD  
2894 - Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study  
Disclosure: Nothing to Disclose

Harrison, Mark, PhD  
1928 - Patient-Physician Communication about Medication Costs in Rheumatoid Arthritis  
Disclosure: Nothing to Disclose

Hattersley, Gary, PhD  
2810 - Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated with Abaloparatide Followed By Alendronate  
Disclosure: Radius Health, Inc., 3

Henderson, Lauren A., MD, MMSc  
927 - The Reprogramming of Regulatory T Cells to a Th17 Phenotype in Systemic Juvenile Idiopathic Arthritis  
Disclosure: Nothing to Disclose

Herath, Kanchana, MD  
883 - Evaluation of Fracture Risk and Osteoporosis in Males with Rheumatoid
Arthritis
Disclosure: Nothing to Disclose

Hernández-Breijo, Borja, PhD
2888 - Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis
Disclosure: Nothing to Disclose

Hessian, Paul A, PhD, BSc (Hons)
929 - Transcriptional Profiling of the Subcutaneous Rheumatoid Nodule: An Insight into Pathogenic Mechanisms and Cellular Content
Disclosure: Nothing to Disclose

Higashioka, Kazuhiko
2801 - A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis
Disclosure: Nothing to Disclose

Hinze, Tanja, M.D.
2917 - Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis
Disclosure: Novartis, 5

Hočevar, Alojzija, MD, PhD
2839 - MiRnora Expression in the Vasculitic Skin Lesions of Adult Patients with IgA Vasculitis
Disclosure: Nothing to Disclose

2842 - Does Leflunomide Have a Role in Giant Cell Arteritis?
Disclosure: Nothing to Disclose

Hong, Huixian
2795 - IL-23 Acts through IL-23R+ Tfh cells to Promote Pathogenic IgG Autoantibody

Huo, Williams, MD
1823 - Loss of Synovial Tissue Resident Macrophages Permits Monocyte to Macrophage Differentiation and Inflammation in Hupo Mice
Disclosure: Nothing to Disclose

Hyrich, Kimme L.
2866 - Biologic Refractory Disease in a Cohort Study of Children and Young People with Juvenile Idiopathic Arthritis from the United Kingdom
Disclosure: Nothing to Disclose
Jafarzadeh, S. Reza, DVM, MPVM, PhD
1947 - Do Changes in Pain Sensitization and Depressive Symptoms Mediate the Effect of Extreme Weight Loss on Knee Pain Improvement?
 Disclosure: Nothing to Disclose

Jaffe, Erica
858 - Measuring Cognitive Load during Arthrocentesis Training: Our Initial Experience
 Disclosure: Nothing to Disclose

Jani, Meghna, MRCP, PhD
961 - The Association of Biologic Drug-Levels with Infection Risk: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
 Disclosure: Grifols for an invited academic talk, 9

2956 - Changing Trends and Prescribing Patterns in Opioid-Treated Primary Care Patients with Non-Cancer Pain over a 10-Year Period
 Disclosure: Nothing to Disclose

Jensen, Thomas Bo, MD
1853 - Paternal Use of Methotrexate (MTX) and Congenital Malformations - a Systematic Review and Meta-Analysis
 Disclosure: Nothing to Disclose

Jin, Yinzhu, MS, MPH
2954 - Factors Related to Initiation of TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
 Disclosure: Nothing to Disclose

Jing, Xiaona
973 - Low-Dose IL-2 Combined with Rapamycin Efficiently Promoted Disease Remission and Recovered the Balance of Th17/Regulatory T Cells in Patients with Refractory Systemic Lupus Erythematosus
 Disclosure: Nothing to Disclose

Jones, Kim, PhD
1838 - Fibromyalgia, Beyond the 2016 Establishment. an Analysis of Novel Symptom Clusters for Differentiating Fibromyalgia from Other Chronic Pain Disorders
 Disclosure: Nothing to Disclose

1946 - Changing the Conversation about Pain: Development and Testing of an Interprofessional Pain CME Applicable for Rheumatologists and Rheumatology Health Professionals
 Disclosure: Nothing to Disclose

Jordan, Jarrat, PhD
2951 - Ustekinumab Treatment Response in SLE Is Associated with Changes in Type II but Not Type I Interferons
 Disclosure: Janssen Research Development, LLC, 3

Jorge, April, MD
2804 - Identifying Lupus Patients in Electronic Health Records: Development and Validation of Machine Learning Algorithms and Application of Rule-Based Algorithms
 Disclosure: Nothing to Disclose

2896 - Increased Mortality Among Patients with Systemic Lupus Erythematosus after Hydroxychloroquine Discontinuation
 Disclosure: Nothing to Disclose

Kachur, Patricia, MD
2847 - Associations between Serum Uric
Acid Level and Coronary Artery Disease
Disclosure: Nothing to Disclose

Kahlenberg, Michelle, MD, PhD
1896 - Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling
Disclosure: Nothing to Disclose

Kamen, Diane L., MD, MSCR
1872 - Safety and Efficacy of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus: Results of an Open-Label Phase I Study
Disclosure: Nothing to Disclose

Karadag, Omer, MD
1884 - Clinical Features and Outcome of Patients with Polyarteritis Nodosa - a Global Collaborative Study
Disclosure: Nothing to Disclose

Kasapcopur, Ozgur
2921 - The Performance of the Newly Proposed EULAR/Acr Classification Criteria in Juvenile-Onset Systemic Lupus Erythematosus
Disclosure: Nothing to Disclose

Kasturi, Shanthini, MD, MS
2911 - Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status
Disclosure: Nothing to Disclose

Katz, Patricia, PhD
2849 - Risk of Obstructive Sleep Apnea in Rheumatoid Arthritis
Disclosure: Bristol-Myers Squibb, 2

2914 - Examination of Psychometric Properties of the Patient-Reported Outcomes Measurement Information System Fatigue 4-Item Short Form in Psoriatic Arthritis
Disclosure: Bristol-Myers Squibb, 2

Kaur, Manjinder, MD
953 - Evaluating MRI-Detected Knee Inflammation Prior to Total Knee Replacement As a Predictive Biomarker of Clinically Important Pain Reduction Two Years Later
Disclosure: Nothing to Disclose

Kawatkar, Aniket
2999 - Does the Incremental Cost of ACPA-Positive Rheumatoid Arthritis Patients Vary By the Care Pathway They Follow?
Disclosure: Bristol-Myers Squibb, 2

Kerschbaumer, Andreas, MD
2878 - Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Disclosure: Bristol-Myers Squibb and Pfizer, 9

Keyes-Elstein, Lynette, DrPH
902 - Longitudinal Trends in Clinical Disease Features after Myeloablative Autologous Stem-Cell Transplantation or Cyclophosphamide in Severe Scleroderma
Disclosure: Nothing to Disclose

Khanna, Dinesh, MD, MS
900 - Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis—Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study
Disclosure: Actelion, 5; Bayer, 2, 5; BMS, 2;
Boehringer Ingelheim, 5; Civi BioPharma, 3; Corbus, 5; Cytori, 5; Eicos Sciences, 1; EMD Serono, 5; Genentech, Inc., 5; GSK, 5; Horizon, 2; Pfizer, Inc., 2; Sanofi-Aventis, 5

898 - Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial
Disclosure: Nothing to Disclose

1879 - The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
Disclosure: Actelion, 5; Bayer, 2, 5; BMS, 2; Boehringer Ingelheim, 5; Corbus, 5; Cytori, 5; Eicos Sciences, 1; EMD Serono, 5; Genentech, Inc., 5; GSK, 5; Horizon, 2; Pfizer, Inc., 2; Sanofi-Aventis, 5

2938 - Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (ACR CRISS) in a Phase 3 Randomized Controlled Trial
Disclosure: Nothing to Disclose

2855 - Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Diraspass
Disclosure: Novartis, 2; Novartis, SOBI, 5

Kiltz, Uta, MD
1865 - Ixekizumab Significantly Improves Self-Reported Overall Functioning and Health in Patients with Active AxSpA Naive to Biologic DMARD Therapy: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
Disclosure: AbbVie Inc., 2, 5; Chugai, 2, 5; Eli Lilly and Co., 2, 5; Grunenthal, 2, 5; Janssen, 2, 5; MSD, 2, 5; Novartis, 2, 5; Pfizer, Inc., 2, 5; Roche, 2, 5; UCB, Inc., 2, 5

Kim, Mimi, ScD
2931 - Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects
Disclosure: Nothing to Disclose

Kivitz, Alan J.
1869 - Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
Disclosure: Celgene, Pfizer, Sanofi/Regeneron, Horizon and Merck, 8; AbbVie, Pfizer, Genentech, UCB, Sanofi/Regeneron and Celgene, 5

Kuemmerle-Deschner, Jasmin B., MD
2855 - Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Diraspass
Disclosure: Novartis, 2; Novartis, SOBI, 5

Kuo, Daniel, MD
2906 - Synovitis Focused Ultrasound in Rheumatoid Arthritis: A Joint Reduction Strategy
Disclosure: Nothing to Disclose

Kwoh, C. Kent, MD
1861 - Lipid Screening in Medicare Beneficiaries with Rheumatoid Arthritis
Disclosure: Nothing to Disclose
Lanata, Cristina, MD
916 - Integrative Analysis of Multi-Omics Data in an Ethnically Diverse Lupus Cohort Identifies Distinct Molecular Subtypes of SLE
Disclosure: Nothing to Disclose

Laskou, Faidra, MRCP
2843 - Leflunomide in Giant Cell Arteritis and Polymyalgia Rheumatica: A Real World Single Centre Experience
Disclosure: Nothing to Disclose

Lassere, Marissa
2957 - Socioeconomic Differences in Opioid Use By People with Inflammatory Arthritis
Disclosure: Nothing to Disclose

Lawson, Daeria O., HBSc, CCRP
2944 - Longitudinal Outcomes and Predictors of E-Learning Effectiveness in Patients with Axial Spondyloarthritis: A Randomized Controlled Trial
Disclosure: Nothing to Disclose

LE JONCOUR, Alexandre
1885 - Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s disease): A Multicenter Study of 224 Patients
Disclosure: Nothing to Disclose

Lee, Jiha, MD, MHS
2998 - Opioid Use Among SLE Patients and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Disclosure: Nothing to Disclose

1918 - Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients
Disclosure: Eli Lilly and Co., 6; Pfizer, Inc., 2

1917 - Physician Opioid Prescribing Patterns and Risk for Chronic Opioid Use Among Rheumatoid Arthritis Patients
Disclosure: Eli Lilly and Co., 6; Pfizer, Inc., 2

2873 - Remaining Pain and Widespread, Non-Inflammatory Pain Distribution during the First 12 Months after RA Diagnosis
Disclosure: Multiple, 2

Liang, Ruifang
1904 - Orphan Nuclear Receptor Rorα Is a Key Regulator of Tgfβ- and WNT-Signaling in Fibrotic Diseases
Disclosure: Nothing to Disclose

Liao, Katherine P., MD, MPH
1891 - Patterns of Biosimilar Use in the Rheumatology Informatics System for Effectiveness (RISE) Registry
Disclosure: Nothing to Disclose

Lim, S. Sam
1844 - Racial Disparities and Accelerated SLE Mortality from a Population-Based Registry: The Georgia Lupus Registry
Disclosure: Nothing to Disclose

1850 - A Population Based Study of High School Academic Outcomes in Individuals with Childhood-Onset Chronic Rheumatic Diseases in Manitoba, Canada
Disclosure: Nothing to Disclose

Lin, Jay
2875 - Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis
Disclosure: Sanofi and Regeneron Pharmaceuticals, Inc., 2
Liu, Jing 896 - Pharmacogenomics Study of Predicting Response of TNF Blocker and Medical Image Progression in Chinese Han Ankylosing Spondylitis Population  
Disclosure: Nothing to Disclose

913 - Risk Factors for Knee Pain Exacerbation on Walking: A within-Person Knee-Matched Study  
Disclosure: Nothing to Disclose

Lochhead, Robert, PhD 951 - IFN-Gamma Production in Lyme Arthritis Synovial Tissue Promotes Differentiation of Fibroblast-like Synoviocytes into Inflammatory Effector Cells  
Disclosure: Nothing to Disclose

Lood, Christian, PhD 2981 - Mitochondrial Extrusion and Autoimmunity in Juvenile Dermatomyositis  
Disclosure: Nothing to Disclose

Lopes, Michelle, MD 853 - Enhanced Type I Interferon Gene Signature in Primary Antiphospholipid Syndrome: Association with Earlier Disease Onset and Preeclampsia  
Disclosure: Nothing to Disclose

946 - Short-Term Safety of Fractional-Dose Yellow Fever Vaccination in Autoimmune Rheumatic Diseases and Kinetics of White Blood Cells  
Disclosure: Nothing to Disclose

Lopez-Olivo, Maria A., MD, PhD 1926 - Effects of Social Networking on Chronic Disease Management in Rheumatoid Arthritis  
Disclosure: Nothing to Disclose

Lu, Bing, MD, DrPH 1906 - Abdominal Obesity and Risk of Developing Rheumatoid Arthritis in Women  
Disclosure: Nothing to Disclose

Lubberts, Erik, PhD 842 - Interleukin 17 Receptor D (IL-17RD) Is Regulated By Pro-Inflammatory Cytokines and Plays a Role in the Development of Collagen-Induced Arthritis  
Disclosure: Nothing to Disclose

Disclosure: Nothing to Disclose

Luu, Queenie, BSc(Med)(Hons), MBBS(Hons), MMed(ClinEpi) 2978 - Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult Idiopathic Inflammatory Myopathies (IIM) in an Australian Cohort  
Disclosure: Nothing to Disclose

MacFarlane, Lindsey A., MD, MPH 1957 - Peri-Operative Glycemic Evaluation Prior to Total Joint Replacement in Patients with and without Diabetes  
Disclosure: Samumed, 5

Maglio, Cristina 1907 - High Serum Adiponectin Associates with the Incidence of Rheumatoid Arthritis in Obese Subjects  
Disclosure: Nothing to Disclose
Majithia, Vikas, MD, MPH  
969 - Obstetric Outcomes in Women with Psoriatic Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011  
Disclosure: Nothing to Disclose

Major, Tanya J., Ph.D.  
871 - Estimates of Diet Quality Explain Less Variability in Serum Urate Levels Than Genetic Factors  
Disclosure: Nothing to Disclose

Makinde, Hadijat M., PhD  
937 - Evidence of a Common Microglial Signature in Models of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’  
Disclosure: Nothing to Disclose

Makiyama, Ayako, MD  
2947 - Peripheral Helper T Cells in Systemic Lupus Erythematosus  
Disclosure: Nothing to Disclose

Makol, Ashima, MD  
1880 - Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)  
Disclosure: Nothing to Disclose

Maksymowych, Walter P., FRCP, MD  
868 - International Multi-Reader Validation of the Outcome Measures in Rheumatology Hip MRI Scoring System (OMERACT HIRISS) for Bone Marrow Lesions in Osteoarthritis  
Disclosure: CaRE rhritis, 9

968 - What Is the Impact of Imaging on Diagnostic Ascertainment of Patients Presenting with Undiagnosed Back Pain in Routine Practice and the Impact of Central Reading? Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort  
Disclosure: CaRE rhritis, 9

2926 - Which MRI Lesions in the Sacroiliac Joint Are Associated with the Diagnosis of Axial Spondyloarthritis after 2 Years Follow up in the Echography in Spondyloarthritis Cohort?  
Disclosure: CaRE rhritis, 9

2927 - What Are the Optimal MRI Lesion Cut-Offs That Define Active and Structural Lesions in the Sacroiliac Joint As Being Typical of Axial Spondyloarthritis By Expert Readers?  
Disclosure: CaRE rhritis, 9

Manasson, Julia, MD  
1829 - Perturbations of the Gut Fungal and Bacterial Microbiome with Biologic Therapy in Spondyloarthritis  
Disclosure: Nothing to Disclose

Manni, Michela, PhD  
2796 - Sex-Based Differences Control ABC Function in Swef-Deficient Mice  
Disclosure: Nothing to Disclose

Manson, Jessica, PhD, MRCP  
931 - Patients with Seropositive Rheumatoid Arthritis Who Do Not Mount a CRP Response When They Have Synovitis Are Immunologically Distinct and Are Poorly Served By Current Management Strategies  
Disclosure: Nothing to Disclose
Maria, Naomi I., PhD
2850 - Human Toll-like Receptor 8 Adversely Affects Placental Development and Pregnancy Outcomes in a Mouse Model of Systemic Lupus Erythematosus
Disclosure: Nothing to Disclose

Marona, José
2891 - Eligibility Criteria for TNFi Therapy in Axial SpA: Going Beyond Basdai
Disclosure: Merck & Co., 2

Martin, Kathryn R, MPH, PhD
2844 - A Mixed-Methods Feasibility Study Exploring the Cultural Adaptation of Walk with Ease to the United Kingdom
Disclosure: Nothing to Disclose

Martínez, Ana, MSc, PhD student
2825 - Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
Disclosure: Nothing to Disclose

McClung, Michael
2811 - Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
Disclosure: Amgen Inc., 5; Radius Health, Inc, 5

McGuire, Dawn, MD
L16 - Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness
Disclosure: OrthoTrophix, Inc, 1, 3

McMahon, Maureen A., MD, MS
1871 - A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE
Disclosure: Nothing to Disclose

McMaster, Christopher, MBBS
1916 - Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy
Disclosure: Nothing to Disclose

Mease, Philip J., MD
2889 - Inhibition of Radiographic Progression and Correlation with Changes in Composite Indices of Disease Activity in Patients with Active Psoriatic Arthritis Treated with Intravenous Golimumab, As Measured in a Phase III Trial
Disclosure: Janssen Research and Development, LLC, 2

Mediero, Aranzazu, PhD
948 - Effects of Antiretroviral Therapy with Tenofovir and Other Antiretroviral Drugs on the Inflammatory State and Bone Remodeling on Newly Diagnosed HIV-Patients at Basal and 3 Months after Starting Treatment
Disclosure: CP15/00053 PI16/0991, 2, 9

Meednu, Nida, PhD
2885 - Expansion of Activated PD-1+ ICOS+ T Follicular and Peripheral Helper Cells in Primary Sjögren’s Syndrome Associates with Abnormalities in B Cell Compartment
Disclosure: Nothing to Disclose

Mendel, Arielle, MD
1856 - Low Aspirin Use and High Prevalence of Preeclampsia Risk Factors Among Pregnant Women in a Multi-National SLE
Inception Cohort
*Disclosure: Nothing to Disclose*

**Meng, Tao**
912 - Association of Adiposity Measures in Childhood and Adulthood with Knee Cartilage Thickness, Volume and Bone Area in Young Adults
*Disclosure: Nothing to Disclose*

**Merola, Joseph F., MD MMSc**
2933 - Non-Invasive Tape Sampling Reveals RNA Gene Clusters in Cutaneous Lupus Erythematosus That Discriminate Affected from Unaffected and Healthy Volunteer Skin
*Disclosure: Biogen, 2, 5, 9*

**Merrill, Joan T., MD**
972 - An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study
*Disclosure: BMS, GSK, 2; BMS, GSK, UCB, Questcor, EMD Serono, Amgen, Celgene, Pfizer, RemeGen, Exagen, MedImmune, Lilly, Janssen, Xencor, Sanofi, Neovacs, Immupharma, Astellas, Glenmark, ILToo, 5; Have given talks for BMS but not for Speakerâ€™s bureau, 9*

**Michailidou, Despina, MD, Ph.D**
2992 - Are Specific Vascular Symptoms in Takayasu’s Arteritis Reflective of Vascular Inflammation, Vascular Damage, or Both?
*Disclosure: Nothing to Disclose*

**Michaud, Kaleb, PhD**
2915 - Can Passively-Collected Phone Behavior Determine Rheumatic Disease Activity?
*Disclosure: Rheumatology Research Foundation and Pfizer, 2; University of Nebraska Medical Center and FORWARD,*

**Mihai, Carina, MD**
1875 - Influence of Setting an Upper Limit of the Modified Rodnan Skin Score As an Inclusion Criterion in Systemic Sclerosis Clinical Trials on the Ratio of Skin Fibrosis Progression Vs. Improvement – an Analysis of the Genisos Cohort
*Disclosure: Nothing to Disclose*

**Mike, Elise, MS**
935 - Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Lipocalin-2
*Disclosure: Nothing to Disclose*

**Mills, Tingting, PhD**
1899 - Down-Regulation of RNA Processing Protein CFIm25 Amplifies Skin Fibrosis By up-Regulating Pro-Fibrotic Transcripts/Proteins in Systemic Sclerosis
*Disclosure: Nothing to Disclose*

**Mogard, Elisabeth, PT**
2887 - Chronic Pain and Assessment of Pain Sensitivity in Patients with Established Axial Spondyloarthritis – a Cross-Sectional Study
*Disclosure: Nothing to Disclose*

**Mok, Chi Chiu, MD**
2892 - Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
*Disclosure: Nothing to Disclose*

**Mollerach, Florencia Beatriz, MD**
2990 - Do Polymyalgia Rheumatica Patients Have an Increased Risk of Cardiovascular Disease, 3
Events?: A Matched-Control Study  
**Disclosure:** Nothing to Disclose

**Morgan, Esi, MD, MSCE**  
981 - New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis  
**Disclosure:** Nothing to Disclose

**Moulton, Vaishali R., MD, PhD**  
936 - Selective Deficiency of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in T Lymphocytes Leads to mTORC1 Activation, Treg Dysfunction and Systemic Autoimmune Disease  
**Disclosure:** Nothing to Disclose

**Mueller, Daniel L., MD**  
2800 - Adenosine 2a Receptor Signals Act to Limit Autoimmune Arthritis By Inhibiting Pathogenic Germinal Center T Follicular Helper (GC-Tfh) Cells  
**Disclosure:** Nothing to Disclose

**Naik, Pooja, Ph.D.**  
2902 - Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells  
**Disclosure:** Nothing to Disclose

**Nault, Tori, MD**  
876 - Dermatomyositis Skin Shares Type I Interferon Overlap with Cutaneous Lupus but Displays Many Unique Expression Changes That May Serve As Biomarkers for Skin Disease  
**Disclosure:** Nothing to Disclose

**Nelson, Winnie, PharmD, MS, MBA**  
2912 - Lupus Flare Activity from the Patient Perspective  
**Disclosure:** Mallinckrodt Pharmaceuticals, 1, 3

**Neogi, Tuhina, MD, PhD, FRCPC**  
1921 - Relation of Sensitization and Conditioned Pain Modulation to Post-Knee Replacement Pain  
**Disclosure:** Nothing to Disclose

**Ng, Sin Ngai, MBchB, FHKAM(Rheumatology)**  
2908 - Agreement between Ultrasound and Whole Body Magnetic Resonance Imaging Assessment of Joint Inflammation and Enthesitis in Rheumatoid Arthritis Patients  
**Disclosure:** Nothing to Disclose

**Nicolai, Rebecca, MD**  
2920 - Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis  
**Disclosure:** Cure JM Foundation, 2

**Niddrie, Fiona, RN**  
976 - Transitioning from Paediatric to Adult Health Services: Development of an Integrated Programme Incorporating Patient and Provider Values  
**Disclosure:** Nothing to Disclose

**Nielsen, Berit Dalsgaard**  
2905 - Ultrasound Diagnosis of Large Vessel Inflammation in New-Onset Treatment-Naïve GCA Patients Using Fluorine-18-Fluorodeoxyglucose PET/CT As the Reference Standard – a Prospective Study of 86 Patients Suspected of GCA  
**Disclosure:** Roche, 9

**Nihtyanova, Svetlana I., MSc MD**  
2935 - A Practical Classification of Systemic
Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification
Disclosure: Nothing to Disclose

Nikiphorou, Elena, MBBS/BSc FRCP MD(Res) PGCE FHEA
1923 - Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Disclosure: Nothing to Disclose

Niles, John L., M.D.
904 - Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry
Disclosure: Nothing to Disclose

Norgeot, Beau
1890 - Longitudinal Deep Learning on Electronic Health Record Data to Predict Future Rheumatoid Arthritis Disease Activity
Disclosure: Nothing to Disclose

Norman, Eric, MS
1828 - Gut-Joint T Cell Trafficking in a Model of Bacteria-Driven Murine IBD-Spa
Disclosure: Nothing to Disclose

Norvang, Vibeke, MD
2985 - Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies
Disclosure: Nothing to Disclose

O'Connor, Anna, MD
2872 - Variation in Predictors of Patient and Physician Defined Flares in Rheumatoid Arthritis
Disclosure: Nothing to Disclose

Arthritis
Disclosure: Nothing to Disclose

Ohnishi, Naoki, MD.
852 - Antigenic Property of Prothrombin/HLA-DR Complex on Procoagulant Cells in Patients with Antiphospholipid Syndrome
Disclosure: Nothing to Disclose

Okamoto, Yuko, MD
2901 - Sputum Neutrophils from Individuals at-Risk for RA Demonstrate Increased Citrullinated Histone H3 Containing Neutrophil Extracellular Traps That Correlate with Sputum Anti-Cyclic Citrullinated Peptide Antibody Levels
Disclosure: Nothing to Disclose

Orange, Dana, MD
1930 - Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Rheumatoid Arthritis Patients in Clinical Remission
Disclosure: Nothing to Disclose

Orbai, Ana-Maria, MD, MHS
964 - Psoriatic Arthritis Impact of Disease (PsAID12) Was Provisionally Endorsed at Omeract 2018 As Core Instrument to Measure Psoriatic Arthritis-Specific Health-Related Quality of Life in Randomized Controlled Trials and Longitudinal Observational Studies
Disclosure: Nothing to Disclose

Ormseth, Michelle J., MD, MSCI
1860 - Development and Validation of a Microrna Panel to Differentiate between Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Control Subjects
Disclosure: Nothing to Disclose
1931 - Abundance of Plasma Microbial Small RNAs Are Predictive of Improvement in Disease Activity after DMARD Initiation for Rheumatoid Arthritis
*Disclosure: Nothing to Disclose*

2816 - Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
*Disclosure: Nothing to Disclose*

**Overbury, Rebecca S., MD, MS**
893 - Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods
*Disclosure: Nothing to Disclose*

**Ozen, Gulsen, MD**
2817 - Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
*Disclosure: Nothing to Disclose*

**Østergaard, Mikkel, MD, PhD, DMSc**
867 - An MRI Guided Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission Improved MRI Inflammation but Not Damage Progression - Results from the Imagine-RA Randomized Controlled Trial
*Disclosure: Nothing to Disclose*

**Pahomov, Elizabeth, M.D.**
959 - The Prevalence of Methotrexate Associated Hepatotoxicity in a Multi-Hospital Health System
*Disclosure: Nothing to Disclose*

**Papo, Matthias**
908 - Early Prediction of Long-Term Evolutionary Profiles of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Based on Baseline and Follow-up Characteristics
*Disclosure: Nothing to Disclose*

**Pappas, Dimitrios A., MD, MPH**
2877 - The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
*Disclosure: Corrona, LLC, 3; Novartis, 9*

**Park, Jun Won**
2890 - Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study
*Disclosure: Nothing to Disclose*

**Patterson, Sarah L., MD**
2858 - Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
*Disclosure: Nothing to Disclose*

**Pellegrini, Christine, PhD**
1948 - Beliefs and Preferences for Reducing Sedentary Time in Those with Current or Past Knee Symptoms
*Disclosure: Nothing to Disclose*

**Perez, Amanda, BS**
2943 - Helping a Non-Urban Community
Walk with Ease: A Feasibility Pilot Study of an Arthritis Activity Intervention  
*Disclosure: Nothing to Disclose*

2812 - Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture  
*Disclosure: Nothing to Disclose*

**Perez-Garcia, Luis F., MD**  
1898 - Type I Interferon-Induced Proteins May Facilitate the Occurrence of Long QT Syndrome (LQTS) in Parallel with Anti-Ro/SSA and Anti-Ro52/TRIM21 Antibody Levels in Patients with Systemic Lupus Erythematos (SLE): A Bench to Bedside Approach  
*Disclosure: Nothing to Disclose*

**Perez-Ruiz, Fernando, MD, PhD**  
869 - Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout  
*Disclosure: Amgen Inc., 5, 8; Asociación de Reumatólogos de Cruces, 2; Grünenthal, 5, 8; Menarini, 5, 8*

**Perez-Sanchez, Carlos, Doctor**  
856 - Integrated mRNA and microRNA Transcriptomes of Monocytes from Antiphospholipid Syndrome Patients Identifies Molecular Networks Related to Their Atherothrombotic Status. Modulatory Effects of *In Vivo* Ubiquinol Supplementation  
*Disclosure: Nothing to Disclose*

**PERS, Yves-Marie**  
949 - Long-Term Rheumatic and Musculoskeletal Disorders Associated to Ebola Virus Infection  
*Disclosure: Nothing to Disclose*

**Peterson, Rosemary, MD**  
2862 - Magnitude of Response to TNF Inhibitors in Children with Spondyloarthritis and Sacroiliitis  
*Disclosure: Nothing to Disclose*

**Petri, Michelle, MD**  
2835 - Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus  
*Disclosure: Amgen Inc., 5; AstraZeneca, 2; Decision Resources, 5; Eli Lilly and Co., 5; EMD Serono, 5; Exagen, 2; GSK, 5; Inova Diagnostic, 5; Janssen, 5; Medscape, 5; Novartis, 5; Quintiles, 5*

2897 - Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy  
*Disclosure: Amgen Inc., 5; AstraZeneca, 2; Decision Resources, 5; Eli Lilly and Co., 5; EMD Serono, 5; Exagen, 2; GSK, 5; Inova Diagnostic, 5; Janssen, 5; Medscape, 5; Novartis, 5; Quintiles, 5*

2929 - Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE  
*Disclosure: Amgen Inc., 5; AstraZeneca, 2; Decision Resources, 5; Eli Lilly and Co., 5; EMD Serono, 5; Exagen, 2; GSK, 5; Inova Diagnostic, 5; Janssen, 5; Medscape, 5; Novartis, 5; Quintiles, 5*

**Phillip, Courtnie, BA**  
1842 - Implementation of an African American Popular Opinion Leader Model to Address Disparities in Lupus Knowledge and Care  
*Disclosure: Nothing to Disclose*

**Piva, Sara R., PhD, PT**  
1953 - Randomized Trial on Exercise at Late-
Stage after Total Knee Replacement  
Disclosure: Nothing to Disclose

**Poddubnyy, Denis, MD**  
2922 - Magnetic Resonance Imaging of Sacroiliac Joints in Patients with Osteitis Condensans Ilii Reveals a Typical Pattern of Lesions Relevant for Differential Diagnosis with Axial Spondyloarthritis  
Disclosure: Nothing to Disclose

**Pons-Estel, Guillermo J., MD, MSc, PhD**  
1874 - Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort  
Disclosure: Nothing to Disclose

**Poulsen, Raewyn, PhD**  
847 - Basic Calcium Phosphate Crystals Induce Osteoarthritis-Associated Changes in Chondrocyte Phenotype through Activation of Calcium/Calmodulin Kinase 2  
Disclosure: Research grants from the Health Research Council of NZ and Arthritis, NZ, 2

**Price, Lori Lyn, MAS, MLA**  
954 - A New Way to Think about Composite Magnetic Resonance Imaging Scores to Measure Osteoarthritis Severity and Progression  
Disclosure: Nothing to Disclose

**Prieto Peña, Diana, MD**  
2974 - Long-Term Survival in Lung Transplantation for Interstitial Lung Disease Due to Rheumatic Systemic Diseases. Study of 26 Cases of a Single Center  
Disclosure: Nothing to Disclose

**Qaiyum, Zoya**  
1832 - Proteomic and Transcriptomic Profiling of Cells in Ankylosing Spondylitis Patients Identifies a Novel, Synovial-Resident CD8+ T Cell  
Disclosure: Nothing to Disclose

**Quartier, Pierre**  
2865 - Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission  
Disclosure: AbbVie, BMS, Novartis, Pfizer, Sanofi, 9; AbbVie, Lilly, Novartis and SOBI, 8; AbbVie, Novartis, Pfizer, SOBI, 9; Novartis and SOBI, 5

**Rahman, M. Arifur**  
1831 - Intestinal Inflammatory Regulation in Murine and Human Spondyloarthropathy Requires High-Affinity T Cell Receptor-Zeta Chain-Associated Protein (ZAP)70-Mediated Runt-Related Transcription Factor (Runx)3 Activity  
Disclosure: Nothing to Disclose

**Rai, Sharan K., MSc**  
874 - Preventing a Large Majority of Incident Gout Cases By Modifying Key Risk Factors: Findings from a Prospective Cohort of 44,629 Men over 26 Years  
Disclosure: Nothing to Disclose

**Ramiro, Sofia, MD, PhD**  
2924 - Spinal Radiographic Progression in Early Axial Spondyloarthritis: 5-Year Data from the DESIR Cohort  
Disclosure: Nothing to Disclose
Ramsey-Goldman, Rosalind, MD, DrPH
2833 - Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Disclosure: Exagen Diagnostics, Inc, 2

Rao, Deepak, MD, PhD
2946 - T Peripheral Helper Cells Are Expanded in the Circulation of Active SLE Patients and Correlate with CD21low B Cells
Disclosure: Amgen Inc., 5; Merck & Co., 2

Rasmussen, Astrid, MD, PhD
2882 - Minimal Progression of Disease Manifestation in Patients with Sjögren’s Syndrome Re-Evaluated Multiple Years after Initial Disease Classification
Disclosure: Nothing to Disclose

Rat, Anne-Christine, MD, PhD
945 - Pain, Functional Limitations and Physical Activity Participation Trajectories in Patients with Symptomatic Knee and Hip Osteoarthritis: A Multi-Trajectory Analysis
Disclosure: Nothing to Disclose

Rauch, Tibor A., Ph.D.
1827 - Genetic Ablation of Phd Finger Protein 19 Gene Promotes Autoimmune Arthritis in Mice
Disclosure: Nothing to Disclose

Reddy, Nithin, BS
879 - IL-31 Protein Expression in Lesional Skin Correlates with Itch in Dermatomyositis
Disclosure: Nothing to Disclose

Regardt, Malin, PhD, OT
2913 - A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An Omeract Report
Disclosure: Nothing to Disclose

Reichenbach, Stephan
957 - Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial
Disclosure: Nothing to Disclose

Retamozo, Soledad, MD, PhD
1915 - Big Data Analysis of Autoimmune Diseases Induced by Cancer Immunotherapies: Identifying Pharmacological Patterns of Organ-Specific Involvement
Disclosure: Nothing to Disclose

2881 - How Immunological Profile Drives Clinical Phenotype of Primary Sjögren’s Syndrome at Diagnosis: Analysis of 10.500 Patients (Sjögren Big Data Project)
Disclosure: Nothing to Disclose

Reynolds, John A.
2836 - Measurement of Interferon Alpha Expression Using Multiple Methodologies Identifies a Signature in a Subgroup of Connective Tissue Disease Patients with Haematological Abnormalities
Disclosure: Nothing to Disclose

Richard, Nicolas, MD
892 - Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
Disclosure: Nothing to Disclose

Richards, J. Steuart, MBBS
882 - Predictors of Chronic Kidney Disease in US Veterans with Rheumatoid Arthritis
Disclosure: Nothing to Disclose

Richter, Michael, MD, MS
1914 - Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A
Single-Center Cohort of 61 Patients
Disclosure: Nothing to Disclose

Rini, Christine, PhD
2942 - Dyadic Study of Partner Social Support for Physical Activity and Its Role in the Initiati
Disclosure: Nothing to Disclose

Ritchlin, Christopher T., MD, MPH
L17 - Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active PsA: Results from a 48-Week Placebo-Controlled, Dose-Ranging Study
Disclosure: UCB, Amgen, Abbvie, 2; UCB, Amgen, AbbVie, Pfizer, Novartis, Lilly, 5

Rodrigues Manica, Santiago, MD
2923 - Is All MRI-SIJ Inflammation the Same? Gradient of Structural Damage with Increasing Cumulative Inflammation at the SIJ Quadrant Level in Axial Spondyloarthritis – 5-Year Data from the DESIR Cohort
Disclosure: Nothing to Disclose

Romich, Ellen, BS
2859 - Do Preventive Cardiology Consults Versus Usual Care Improve Cardiovascular Risk Factor Assessment and Management in Patients with Rheumatoid Arthritis?
Disclosure: Nothing to Disclose

Rubinstein, Tamar, MD, MS
914 - Increased Adverse Childhood Experiences in Children with Arthritis: An Analysis of the National Survey of Children’s Health
Disclosure: Nothing to Disclose

1847 - Screening Youth with Lupus for Depression and Anxiety in Pediatric Rheumatology Clinics
Disclosure: Nothing to Disclose

Saag, Kenneth, MD, MSc
873 - General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
Disclosure: AstraZeneca, Horizon, SOBI, Takeda, 2, 5

Sacre, Karim, MD, PhD
1912 - Treatment of Cardiac Sarcoidosis: A Comparative Study of Steroids Alone Versus Steroids Associated with Immunosuppressive Drugs
Disclosure: Nothing to Disclose

2970 - In Idiopathic Retroperitoneal Fibrosis, Persistent FDG PET Uptake Helps Identifying Patients at Risk for Relapse
Disclosure: Nothing to Disclose

Sammel, Anthony, MBBS BEng FRACP
L15 - The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
Disclosure: Arthritis Australia, 2

Sanchez-Lopez, Elsa, PhD
2968 - Role of Choline in Gouty Inflammation
Disclosure: Nothing to Disclose

Sandhu, Avneek Singh, MD
2972 - Multicentric Reticulohistiocytosis (1980-2017): A Rare Disease, Commonly Associated with Malignancy and
Autoimmunity
Disclosure: Nothing to Disclose

Sandigursky, Sabina, MD
2797 - Regulation of Autoimmune T Cells By the Co-Receptors CD28 and PD-1
Disclosure: Nothing to Disclose

Santos Faria, Daniela, MD
2823 - Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
Disclosure: Nothing to Disclose

Sapao, Paulene
1901 - Reduced SPAG17 Expression Links Dysfunctional Cilia, Morphogen Signaling Activation and Multiple Organ Fibrosis: Novel Target for Systemic Sclerosis
Disclosure: Nothing to Disclose

Sarica, Shifa, MPH
909 - Temporal Trends of ANCA-Associated Vasculitis Comorbidities: Results from a National, Longitudinal, Matched-Cohort Study
Disclosure: Nothing to Disclose

Sauer, Brian C., PhD
2870 - Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Disclosure: Amgen Inc., 2

Scherlinger, Marc
947 - Clinical Characteristics and Outcome after Treatment of a National Cohort of PCR-Positive Lyme Arthritis
Disclosure: Nothing to Disclose

Schmajuk, Gabriela, MD, MSc
1887 - Practice Variation in Prescriptions of Non-TNFi Biologics and Tofacitinib: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Disclosure: Pfizer, Inc., 2

2860 - Disease Activity and Its Measurement in Patients with RA across the U.S.: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Disclosure: Pfizer, Inc., 2

Schnitzer, Thomas J.
L20 - Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
Disclosure: AbbVie Inc., 5, 9; Aptinyx, 5; Eli Lilly and Co., 5, 9; Genzyme, 5; Grunenthal, 9; Pfizer, Inc., 5, 9; Radius, 9; Regeneron, 5, 9; Vertex, 5

Schulert, Grant, MD, PhD
923 - Neutrophils from Children with Systemic JIA Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease
Disclosure: Nothing to Disclose

Schwartz, Noa, MD, MS
938 - Dermal Lymphatic Dysfunction and Photosensitivity in the MRL/Lpr Lupus Model
Disclosure: Nothing to Disclose

Sciascia, Savino, MD
2893 - Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and
Thrombotic Microangiopathy: A Multicenter Cohort Study  
**Disclosure: Nothing to Disclose**

**Seven, Sengül**  
864 - The Diagnostic Utility of the Relation between MRI Bone Marrow Edema and Other Types of MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis  
**Disclosure: Nothing to Disclose**

**Sevim, Ecem, MD**  
854 - First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry")  
**Disclosure: Nothing to Disclose**

**Shadick, Nancy A., MD, MPH**  
2986 - The Impact of Exercise and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study  
**Disclosure: Amgen, Mallinckrodt, Bristol-Myers Squibb, Sanofi-Regeneron, 2; Bristol-Myers Squibb, 5**

**Shelef, Miriam A., MD, PhD**  
2794 - Peptidylarginine Deiminases Are Required for Normal Immunoglobulin G Half-Life  
**Disclosure: Nothing to Disclose**

**Sherina, Natalia, MSc**  
2793 - Molecular Mimicry and Autoimmunity: Anti-*P. Gingivalis* antibody Response in ACPA-Positive Rheumatoid Arthritis  
**Disclosure: Nothing to Disclose**

**Shin, Joseph**  
1902 - Pathogenic and Therapeutic Modulation of Activating Epigenetic Memory at a Novel Enhancer for TGFβ2 in Systemic Sclerosis  
**Disclosure: Nothing to Disclose**

**Shipman, William D.**  
2853 - A Protective Langerhans Cell-Keratinocyte Axis That Is Dysfunctional in Photosensitivity  
**Disclosure: Nothing to Disclose**

**Sieghart, Daniela, PhD**  
1859 - The Prognostic Value of Autoantibody Isotypes for Predicting Therapeutic Responses to Methotrexate in Patients with Rheumatoid Arthritis  
**Disclosure: Nothing to Disclose**

**Singh, Jasvinder A., MD, MPH**  
944 - Gout: A Potential Risk Factor for Uveitis in the Older Adults?  
**Disclosure: Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC, Medscape, Fidia pharmaceuticals and the American College of Rheumatology, 5; Takeda, Savient, 2**

1955 - Race Is Associated with Discharge Disposition after Total Knee Arthroplasty (TKA), Which Is Associated with 90-Day Readmission Rate  
**Disclosure: Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC, Medscape, Fidia pharmaceuticals and the American College of Rheumatology, 5; Takeda, Savient, 2**

845 - New Insights in Lupus Dermatitis: Differential Regulation and Roles of Tissue-
Resident Dendritic Cell Subsets in the Pathogenesis of Autoimmune Skin Inflammation
Disclosure: Nothing to Disclose

1888 - SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015
Disclosure: Nothing to Disclose

2803 - 48-Year Trends in Systemic Sclerosis Mortality in the United States, 1968-2015: Steady Decrease for 15 Years after 33 Years of Continuous Increase
Disclosure: Nothing to Disclose

Slight-Webb, Samantha, PhD
2837 - Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients
Disclosure: Nothing to Disclose

2949 - African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Disclosure: Nothing to Disclose

Smith, Isaac, MD
2819 - Alcohol Consumption and the Risk of Coronary Heart Disease and Mortality in Patients with Rheumatoid Arthritis
Disclosure: Resident Preceptorship Grant from the Rheumatology Research Foundation, 2

Smolen, Josef S.
889 - Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Disclosure: AbbVie Inc., 2, 5

Sodin Semrl, Snezna, PhD
2840 - MiR-125-b Is a Promising Biomarker for Giant Cell Arteritis in Patients with Negative Temporal Artery Biopsy Examination
Disclosure: Nothing to Disclose

Solomon, Daniel, MD, MPH
2952 - Major NSAID Toxicity: Derivation and Internal Validation of a Simple Clinical Risk Score
Disclosure: Nothing to Disclose

Sontichai, Watchareewan, MD
1846 - Menarchal Status at Diagnosis and Final Height in Females with Childhood-Onset Systemic Lupus Erythematosus
Disclosure: Nothing to Disclose

Sparks, Jeffrey A., MD, MMSc
884 - Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Disclosure: Nothing to Disclose

941 - Causal Inference Methods for the Effect of Rheumatoid Arthritis on Mortality Independent of Lifestyle and Clinical Factors before and after RA Diagnosis
Disclosure: Nothing to Disclose

1909 - Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women
Disclosure: Nothing to Disclose

Srinivasan, Sachin, MD
1835 - Diagnosis of Fibromyalgia: Disagreement between Fibromyalgia...
Criteria and Clinician-Based Fibromyalgia Diagnosis in a University Clinic
*Disclosure: Nothing to Disclose*

**Stamatis, Pavlos, MD**
1883 - Infections Are Associated With Increased Risk of Giant Cell Arteritis - a Population-Based Case-Control Study From Southern Sweden
*Disclosure: Nothing to Disclose*

2991 - Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
*Disclosure: Nothing to Disclose*

**Stamp, Lisa K., FRACP, PhD**
2879 - Plasma IL-23 and IL-25 Predict Response to Anti-TNF-α Therapy in Rheumatoid Arthritis
*Disclosure: Amgen Inc., 8*

**Stevens, Randall**
1922 - Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
*Disclosure: Centrexion Therapeutics, 3*

**Stever, Jacob R., M.D.**
2871 - Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis
*Disclosure: Nothing to Disclose*

**Stewart, Sarah, PhD**
2846 - Foot and Lower Limb Characteristics in People with SLE: A Comparison with Age- and Sex-Matched Healthy Control Participants
*Disclosure: Nothing to Disclose*

**Stoeger, Zev**
1893 - Indoleamine-2,3-Dioxygenase in Murine and Human Systemic Lupus Erythematosus
*Disclosure: Nothing to Disclose*

**Studenic, Paul, MD**
2876 - Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis
*Disclosure: Nothing to Disclose*

**Sule, Gautam, Ph.D.**
851 - Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome
*Disclosure: Nothing to Disclose*

862 - Addressing the Pediatric Rheumatology Workforce Shortage: Results from the American College of Rheumatology Annual Pediatric Residents Program
*Disclosure: Nothing to Disclose*

**Suliman, Yossra A, MD**
2937 - Anti-Vinculin Antibodies in Systemic Sclerosis (SSc): A Potential Biomarker Linking Vascular and Gastrointestinal System Involvement in Two Phenotypically Distinctive SSc Groups
*Disclosure: Nothing to Disclose*

**Suryawanshi, Hemant, PhD**
924 - 10X Genomics-Based Single-Cell RNA-Seq and Low Input RNA-Seq Identify a Transcriptional Landscape Supporting Interferon in the Pathogenesis of Autoimmune-Associated Congenital Heart Block
*Disclosure: Nothing to Disclose*
2950 - 10X Genomics-Based Single-Cell RNA-Seq Analysis Identifies a Transcriptional Landscape of Inflammation and Fibrosis in Lupus Nephritis

*Disclosure: Nothing to Disclose*

**Svensson, Mattias N. D., Ph.D.**
1825 - Rheumatoid Arthritis Associated Haploinsufficiency in PTPN2 Enhances Severity of IL-17 Mediated Autoimmune Arthritis

*Disclosure: Nothing to Disclose*

**Svenungsson, Elisabet, Professor**
855 - IgG Antiphospholipid Antibodies, -a Common but Neglected Finding in Patients with Myocardial Infarction

*Disclosure: Nothing to Disclose*

**Takanashi, Satoshi, MD**
877 - Serum Krebs Von Den Lungen-6 Is a Useful Biomarker for Assessing Activity of Myositis-Associated Interstitial Lung Disease

*Disclosure: Nothing to Disclose*

**Takeno, Mitsuhiro, MD, PhD**
2841 - Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup

*Disclosure: Celgene Corporation, 2*

**Tamirou, Farah, MD**
1945 - Early Prediction of Long-Term Renal Outcomes in Lupus Nephritis Using Hazard Index Equations

*Disclosure: Nothing to Disclose*

**Tanaka, Yoshiya**
887 - Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards

*Disclosure: Astellas Pharma, Inc., 2, 5, 9*

2820 - Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial

*Disclosure: Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, AbbVie, YL Biologics, Bristol-Myers Squibb, GSK, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, Asahi Kasei, 8; Mitsubishi-Tanabe, Bristol-Myers Squibb, Eisai, Chugai, Takeda, AbbVie, Astellas, Daiichi-Sankyo, Ono, MSD, Taisho-Toyama, 2*

**Tani, Chiara**
1927 - Do Remission and Low Disease Activity State Go Hand in Hand with Patient’s Perception of Disease Burden and Quality of Life in Systemic Lupus Erythematosus?

*Disclosure: Nothing to Disclose*

**Tarallo, Miriam**
2994 - Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK

*Disclosure: Pfizer, Inc., 1, 3*
Tedeschi, Sara K., MD, MPH
2895 - Effect of Vitamin D on Serum Markers of Bone Turnover in SLE in a Randomized Controlled Trial
Disclosure: Nothing to Disclose

Teitsma, Xavier M, MSc
2899 - Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway
Disclosure: Nothing to Disclose

Terbrueggen, Robert, PhD
917 - Type 1 Interferon Levels Correlates with Age of Diagnosis and Ethnicity in Systemic Lupus Erythematosus
Disclosure: DxTerity, 1, 3, 4

Terrier, Benjamin, MD, PHD
2934 - Myocardial Microscopic Fibrosis Assessed By T1 Mapping Sequences on Cardiac Magnetic Resonance Imaging Predicts Cardiac Events in Systemic Sclerosis: Data from a Prospective Cohort Study on 40 Patients
Disclosure: Nothing to Disclose

Terslev, Lene, MD, PhD
2966 - Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Disclosure: Novartis, AbbVie, Pfizer, UCB, Roche and MSD, 8

Thiele, Ralf G., MD, RhMSUS
2904 - Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Disclosure: AbbVie Inc., 8; Amgen Inc., 8

Thoma, Louise, PT, PhD
1954 - Factors Associated with Overweight or Obesity in Athletes 5 Years after Anterior Cruciate Ligament Injury
Disclosure: Nothing to Disclose

Thompson, Gwen
907 - Characterization of Preferential Recognition of a Chimeric Recombinant Proteinase 3 Variant By Anti-Neutrophil Cytoplasmic Antibodies
Disclosure: Nothing to Disclose

Tieu, Joanna
2971 - Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease: Long Term Outcomes
Disclosure: Roche, 2

Toledo, Diana M., MS
1903 - Molecular Analysis of a Skin Equivalent Tissue Culture Model System of Systemic Sclerosis Using RNA Sequencing, Epigenetic Assays, Histology, and Immunoassays
Disclosure: Nothing to Disclose

Toral, Priscilla, LCSW
1951 - The Effect and Psychosocial Impact of a Longstanding Telephone Peer Counseling Service on Volunteers with Systemic Lupus Erythematosus
Disclosure: Nothing to Disclose

Tselios, Konstantinos, MD, PhD
1873 - Age- and Cause-Specific Standardized Mortality Ratio of Systemic Lupus Erythematosus Patients in Ontario, Canada over 43 Years (1971-2013)
Disclosure: Nothing to Disclose

1944 - Does Renin Angiotensin System Blockade in Addition to Immunosuppressive Therapy Improve Proteinuria in Acute Lupus
Nephritis?  
Disclosure: Nothing to Disclose

**Tsoukas, Paul, MD**  
925 - Abortive Viral Infection Becomes Macrophage Activation Syndrome in Mice with Chronically Elevated Interleukin-18: Evidence for Synergy with Cytotoxic Impairment  
Disclosure: Nothing to Disclose

**Tucker, Lori, MD, FRCPC**  
2918 - Physical Activity in Canadian Children with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)  
Disclosure: Nothing to Disclose

**Uchida, Haruhito A., MD, PhD**  
1882 - Characteristics and Treatment Outcomes of Takayasu Arteritis in a Nationwide, Retrospective Cohort Study in Japan  
Disclosure: Nothing to Disclose

**Ugurlu, Serdal, MD**  
2975 - Anti-Il-1 Therapies in Patients with Familial Mediterranean Fever Related AA-Amyloidosis  
Disclosure: Nothing to Disclose

**USLU YURTERI, Emine**  
2993 - Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis  
Disclosure: Nothing to Disclose

**Vallier, Marie, PhD**  
2829 - The Response to TNF-Blockers Treatment of Spa Patients Is Influenced By the Interplay between HLA-B27 and Gut Microbiota Composition at Baseline  
Disclosure: Nothing to Disclose

**van Dam, Laura**  
2792 - The Effect of B Cell Targeted Therapies on Autoantibodies and Excessive Neutrophil Extracellular Trap Formation in Systemic Lupus Erythematosus  
Disclosure: Nothing to Disclose

**van der Heijde, Désirée**  
1864 -Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial  
Disclosure: AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB Pharma, 5; Imaging Rheumatology BV, 3

**Van Raemdonck, Katrien, PhD**  
840 - The CCL21/CCR7 Axis Drives Vascular, Inflammatory and Destructive Remodeling in Rheumatoid Arthritis  
Disclosure: Nothing to Disclose

**van Vollenhoven, Ronald**  
891 - A Phase 3, Randomized, Controlled
Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis  
**Disclosure:** AbbVie, Arthrogen, BMS, GSK, Lilly, Pfizer, UCB, 2; AbbVie, AstraZeneca, Biotest, BMS, Celgene, GSK, Janssen, Lilly, Medac, Merck, Novartis, Pfizer, Roche, UCB, 9

Volkmann, Elizabeth R., M.D., M.S.  
1877 - Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression  
**Disclosure:** Nothing to Disclose

Walitt, Brian, MD MPH  
1836 - Fibromyalgia Diagnosis and Biased Assessment: Sex, Prevalence, Biology and Bias  
**Disclosure:** Nothing to Disclose

Wallace, Beth, MD, MSc  
1889 - Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population  
**Disclosure:** Nothing to Disclose

970 - Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study  
**Disclosure:** Eli Lilly and Company, EMD Merck Serono, Pfizer, GSK, 5

1886 - Phenotypic Subgroups in IgG4-Related Disease – a Cluster Analysis  
**Disclosure:** Nothing to Disclose

Wallace Fugle, Caroline, BS  
1895 - Marked Immune Cell Subset Changes in Refractory Lupus Patients in a Phase I Trial of Allogenic Mesenchymal Stem Cells  
**Disclosure:** Nothing to Disclose

Walsh, Jessica, MD  
910 - In Diagnostic Prevalence and Treatment Patterns of Male and Female Ankylosing Spondylitis Patients in the United States, 2006-2016  
**Disclosure:** Eli Lilly and Company, 5

Wang, Meiyiing  
1857 - Low Molecular Weight Heparin and Aspirin Combination Therapy Modulates Th1/Th2 Cell Imbalance in Pregnant Patients with Antiphospholipid Antibody-Associated Recurrent Pregnancy Loss  
**Disclosure:** Nothing to Disclose

Warrell Jr., Raymond P., MD  
2967 - Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity  
**Disclosure:** Relburn-Metabolomics, Inc., 1

Wasén, Caroline  
933 - Inflammation in the Hippocampus Affects Insulin-like Growth Factor-1 Receptor Signaling and Contributes to Neurological Sequelae in Rheumatoid Arthritis  
**Disclosure:** Nothing to Disclose

Wei, Jie, PhD  
2848 - Racial Disparities in Utilization of Knee Replacement: Data from the Osteoarthritis Initiative  
**Disclosure:** Nothing to Disclose

928 - Single Cell RNA- Sequencing of Rheumatoid Synovial Fibroblasts Reveals a
Disease-Associated Spatial Gradient Modulated By Inductive Notch Signaling
Disclosure: Roche, 2

Weinblatt, Michael, MD
2815 - Cardiovascular Safety - Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
Disclosure: Abbvie, Amgen, BMS, Crescendo Bioscience, Corrono, GSK, Gilead, Eli Lilly and Company, Lycera, Merck, Novartis, Pfizer, Roche, Samsung, Set Point, UCB, 5; Amgen, BMS, Crescendo Bioscience, Sanofi/Regeneron, 2; Lycera, Canfite, Scipher, Vorso, Inmedix, 1

886 - Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis
Disclosure: Abbvie, Amgen, BMS, Crescendo Bioscience, Corrono, GSK, Gilead, Eli Lilly and Company, Lycera, Merck, Novartis, Pfizer, Roche, Samsung, Set Point, UCB, 5; Amgen, BMS, Crescendo Bioscience, Sanofi/Regeneron, 2; Lycera, Can-fite, Scipher, Vorso, Inmedix, 1

Werth, Victoria P., MD
2977 - Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
Disclosure: Corbus Pharmaceuticals, Inc., 5, 9

Whitfield, Michael L., PhD
1876 - Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant
Disclosure: Nothing to Disclose

Wimmer, Maggie
2940 - Complementary Practices As Alternatives to Pain: Effectiveness of a Pain Management Program for Patients in an Orthopedic Clinic
Disclosure: Nothing to Disclose

Wincup, Chris
2834 - The Presence of Anti-Rituximab Antibodies Predicts Infusion-Related Reactions in Patients with Systemic Lupus Erythematosus
Disclosure: Nothing to Disclose

Wu, Dongze, PhD
865 - Structural and Microstructural Intraarticular Bone Changes at the Metacarpal Heads in Patients with Psoriatic Arthritis Compared to Controls: A HR-pQCT Study
Disclosure: Nothing to Disclose

Yang, Annie, MD
2909 - Diagnostic and Prognostic Value of Ultrasound Compared with Plain Radiography in Knee Osteoarthritis
Disclosure: Nothing to Disclose

Yasin, Shima, MD, MSc
2919 - An Epidemic: Severe Lung Disease in Patients with Systemic Juvenile Idiopathic Arthritis, Risk Factors and Predictors
Disclosure: Nothing to Disclose

Yildirim-Toruner, Cagri, MD
2963 - Improving Clinically Inactive Disease in Patients with Juvenile Idiopathic Arthritis-
Ying, David, MD
2802 - Risk of Ischemic Stroke in Veterans with Systemic Sclerosis: A Nationwide Cohort Study
Disclosure: Nothing to Disclose

Yip, Allison, MS
859 - Using Online Simulation of Pediatric Musculoskeletal Cases to Evaluate How Knowledge of Costs Affects Diagnostic Workup
Disclosure: Nothing to Disclose

Yokose, Chio, MD
866 - Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy
Disclosure: Nothing to Disclose

Yoshimoto, Keiko, PhD
843 - Localization of the Voltage-Gated Sodium Channel 1.7 in Peripheral Monocytes Contributes to Activation of BAFF Signaling in Monocytes of Patients with Primary Sjögren’s Syndrome
Disclosure: Nothing to Disclose

Yue, Jiang, PhD
2845 - A Close Relationship between a Novel Visceral Adiposity Index and Bone Microstructure in Female Early Rheumatoid Arthritis Patients: A 1-Year Follow-up Study By HR-pQCT
Disclosure: Nothing to Disclose

Yun, Huifeng
2856 - Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the Acr’s RISE Registry
Disclosure: Bristol Myers Squibb, 2

Zhang, Peilin, MD, Ph.D.
2883 - Testing for Anti-Microbial Antibodies with Cross-Reactivity to Human Tissue in Autoimmune Diseases
Disclosure: Owner of the company, 4

1939 - Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trial
Disclosure: Nothing to Disclose

1937 - Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis
Disclosure: Nothing to Disclose

2832 - Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2
Disclosure: Nothing to Disclose

850 - Long Term Efficacy of Cartilage Repair Induced By scSOX9 in Situ with Bone Marrow-Derived Mesenchymal Stem Cells
Disclosure: Nothing to Disclose

1908 - Bariatric Surgery Does Not Affect the Incidence of Rheumatoid Arthritis in Obese Subjects
Disclosure: Nothing to Disclose

Zheng, Boyang, MD
1878 - Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index
Disclosure: Nothing to Disclose
ZHENG, SONGGUO
844 - Differential Roles of Tnfα-TNFR1 and Tnfα-TNFR2 in the Differentiation and Function of Induced CD4⁺Foxp3⁺ Treg Cells in Autoimmune Diseases
Disclosure: Nothing to Disclose

Zhou, Cheng, PhD
846 - CD14 Deficiency Dampens Osteoclastogenesis and Alters Bone Remodeling in a Murine Model of Osteoarthritis
Disclosure: Nothing to Disclose

849 - Constructing a Macrophage Infiltration Timeline in a Murine Model of Osteoarthritis
Disclosure: Nothing to Disclose

Ziaee, Saba, MD
1913 - Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
Disclosure: Nothing to Disclose

Zimba, Olena
2989 - Cardiac Involvement in Systemic Vasculitis: A Retrospective Pathological Study
Disclosure: Nothing to Disclose